Hepatitis risk in cardiac surgery patients receiving factor IX concentrates.
Experience with the clinical use and hepatitis risks of factor IX concentrate (Proplex) in cardiac surgical patients is presented in this report. Seventy-five patients received the concentrate for severe intraoperative or postoperative hemorrhage and 75 patients constituted matched controls. The incidence of probable type B viral hepatitis in patients receiving factor IX concentrate was 13.8 percent (four of 29) versus zero percent (zero of 29) in control patients (difference not significant). However, there was a greater incidence (p less than 0.05) of anti-HBs in patients receiving factor IX concentrate as compared to control subjects. No hepatitis-associated deaths or major morbidity were noted in these patients. It is confirmed that factor IX concentrate carries an associated significant risk of hepatitis. However, its use is justified in certain severe, acquired coagulopathies in which conventional platelet and fresh-frozen plasma therapy is inadequate.
D002140:California; D006348:Cardiac Surgical Procedures; D005164:Factor IX / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006470:Hemorrhage / Q000517:prevention & control; D006488:Hemostasis, Surgical / Q000009:adverse effects*; D006490:Hemostatics / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006509:Hepatitis B / Q000453:epidemiology*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006514:Hepatitis B Surface Antigens / Q000032:analysis; D006801:Humans; D008875:Middle Aged; D011183:Postoperative Complications / Q000517:prevention & control; D012189:Retrospective Studies; D012306:Risk; D065227:Transfusion Reaction
D006490:Hemostatics; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D005164:Factor IX